You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

 

Online download statistics by month:

Online download statistics by month: March 2024 to October 2025

AbstractFullPdf
Mar 2024434443180
Apr 202425726483
May 202428828942
Jun 202421821998
Jul 2024432434102
Aug 202418218284
Sep 202415315577
Oct 202413213360
Nov 202414614865
Dec 202416517377
Jan 2025187187116
Feb 2025304308114
Mar 2025174179120
Apr 2025220223136
May 202510911169
Jun 2025107110192
Jul 2025110
Oct 2025550
Total351435641615